Multiple Sclerosis Discovery Forum

Inspiring Connections

Most Viewed

Prediction of oxygen uptake during walking in ambulatory persons with multiple sclerosis.
Rituximab (marketed as Rituxan), Information
Comprehensive follow-up of the first genome-wide association study of multiple sclerosis identifies KIF21B and TMEM39A as susceptibility loci.
Annualized relapse rate of first-line treatments for multiple sclerosis: a meta-analysis, including indirect comparisons versus fingolimod.
FTY720 impairs CD8 T-cell function independently of the sphingosine-1-phosphate pathway.
Extension CombiRx data show no benefit of combined MS drugs
CCR2 defines in vivo development and homing of IL-23-driven GM-CSF-producing Th17 cells.
Dimethyl fumarate (BG-12, Tecfidera) - NICE says yes in draft final guidance
Emerging oral agents for multiple sclerosis.
Individual oligodendrocytes have only a few hours in which to generate new myelin sheaths in vivo.
Channelopathy-related SCN10A gene variants predict cerebellar dysfunction in multiple sclerosis.
Effect of disease-modifying therapies on brain volume in relapsing-remitting multiple sclerosis: results of a five-year brain MRI study.
Gene Expression & Signaling in the Immune System
Increased incidence of central nervous system hemorrhages in patients with secondary acute promyelocytic leukemia after treatment of multiple sclerosis with mitoxantrone?
Comparison of subcutaneous interferon beta-1a with glatiramer acetate in patients with relapsing multiple sclerosis (the REbif vs Glatiramer Acetate in Relapsing MS Disease [REGARD] study): a multicentre, randomised, parallel, open-label trial.
A newborn with Pierre Robin sequence after preconceptional mitoxantrone exposure of a female with multiple sclerosis.
Chemotactic Cytokines: Gordon Research Conference on Molecular and Cellular Mechanisms in Health and Disease
Immunosuppressive properties of mesenchymal stem cells: advances and applications.
Study of teriflunomide in reducing the frequency of relapses and accumulation of disability in patients with multiple sclerosis (TEMSO)
Genzyme Announces EMA Accepts Oral Teriflunomide Marketing Application for Treatment of Multiple Sclerosis
Lithium Controls Central Nervous System Autoimmunity through Modulation of IFN-γ Signaling.
Cognitive Impairment in Multiple Sclerosis: Clinical Manifestation, Neuroimaging Correlates, and Treatment.
Multiple sclerosis and neuromyelitis optica spectrum disorders: some similarities in two distinct diseases.
Epigenetic Modulation of Human Induced Pluripotent Stem Cell Differentiation to Oligodendrocytes.
Interferon-beta in pediatric multiple sclerosis patients: safety in short-term prescription.

Pages